The stock of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) is a huge mover today! About 289,756 shares traded hands. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has risen 60.13% since March 7, 2016 and is uptrending. It has outperformed by 52.54% the S&P500.
The move comes after 7 months positive chart setup for the $1.22B company. It was reported on Oct, 10 by Barchart.com. We have $40.54 PT which if reached, will make NASDAQ:SUPN worth $780.80 million more.
Analysts await Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to report earnings on November, 1. They expect $0.21 earnings per share, up 162.50% or $0.13 from last year’s $0.08 per share. SUPN’s profit will be $10.36M for 29.43 P/E if the $0.21 EPS becomes a reality. After $0.18 actual earnings per share reported by Supernus Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 16.67% EPS growth.
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Ratings Coverage
Out of 3 analysts covering Supernus Pharmaceuticals (NASDAQ:SUPN), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Supernus Pharmaceuticals has been the topic of 6 analyst reports since August 26, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by Jefferies on Thursday, August 4. The firm has “Outperform” rating given on Wednesday, October 28 by Northland Capital. Piper Jaffray downgraded the shares of SUPN in a report on Monday, July 18 to “Neutral” rating. Zacks downgraded the shares of SUPN in a report on Wednesday, August 26 to “Hold” rating. Northland Capital downgraded the shares of SUPN in a report on Monday, July 18 to “Market Perform” rating. Northland Capital maintained Supernus Pharmaceuticals Inc (NASDAQ:SUPN) rating on Thursday, November 5. Northland Capital has “Outperform” rating and $27 price target.
According to Zacks Investment Research, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.”
Insitutional Activity: The institutional sentiment increased to 1.26 in 2016 Q2. Its up 0.11, from 1.15 in 2016Q1. The ratio improved, as 27 funds sold all Supernus Pharmaceuticals Inc shares owned while 62 reduced positions. 25 funds bought stakes while 87 increased positions. They now own 45.62 million shares or 4.54% more from 43.64 million shares in 2016Q1.
The Quebec – Canada-based Sector Pension Investment Board has invested 0.01% in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Glenmede Tru Na, a Pennsylvania-based fund reported 1.78M shares. State Street holds 0% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) for 1.15 million shares. Bank & Trust Of Montreal Can reported 9,807 shares or 0% of all its holdings. Teachers Retirement Of The State Of Kentucky last reported 16,400 shares in the company. Alphaone Inv Llc accumulated 231,667 shares or 1.74% of the stock. State Of Tennessee Treasury Department accumulated 0% or 26,730 shares. Northpointe has invested 1.83% of its portfolio in Supernus Pharmaceuticals Inc (NASDAQ:SUPN). Paradigm Asset Co Lc reported 4,750 shares or 0% of all its holdings. White Pine Lc last reported 43,100 shares in the company. Ubs Asset Management Americas has 0% invested in the company for 17,500 shares. Ladenburg Thalmann Ser holds 3,734 shares or 0% of its portfolio. Renaissance Group Inc Limited Liability last reported 17,197 shares in the company. Geode Limited Liability Co accumulated 276,082 shares or 0% of the stock. California Pub Employees Retirement Sys reported 66,400 shares or 0% of all its holdings.
Insider Transactions: Since April 11, 2016, the stock had 0 insider buys, and 1 insider sale for $50,000 net activity. PATRICK GREGORY S sold $50,000 worth of stock. 30,762 shares were sold by Bhatt Padmanabh P., worth $507,228 on Monday, April 11.
Another recent and important Supernus Pharmaceuticals Inc (NASDAQ:SUPN) news was published by Seekingalpha.com which published an article titled: “Supernus: Reasonable Valuation And Strong Future Growth” on October 05, 2016.
SUPN Company Profile
Supernus Pharmaceuticals, Inc. (Supernus), incorporated on March 30, 2005, is a pharmaceutical firm focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Firm offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR). It is also engaged in developing multiple product candidates in psychiatry for the treatment of Impulsive Aggression (IA) and attention deficit hyperactivity disorder (ADHD). The Company’s psychiatry product candidates include SPN-810 (molindone hydrochloride) and SPN-812 (viloxazine hydrochloride). It is also developing SPN-810 as a treatment for IA in patients who have ADHD and SPN-812 for the treatment of ADHD. It is also developing SPN-809 (viloxazine hydrochloride) for the treatment of depression. The Firm markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.